Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Menstrual cycle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    409 result(s) found for: Menstrual cycle. Displaying page 21 of 21.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    EudraCT Number: 2009-013064-40 Sponsor Protocol Number: HZC102970 Start Date*: 2009-10-14
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects w...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) NL (Completed) DK (Completed) IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003333-42 Sponsor Protocol Number: EZH-302 Start Date*: 2020-11-09
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refr...
    Medical condition: Relapsed/refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 10016903 - Follicle centre lymphomas, follicular grade I, II, III 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003206-25 Sponsor Protocol Number: NRL001-01/2011(SEFI) Start Date*: 2012-01-25
    Sponsor Name:Norgine Ltd
    Full Title: A multi-centre, phase II, double-blind, randomised, placebo-controlled, parallel group, dose-ranging study in patients with faecal incontinence; to evaluate the efficacy, safety and tolerability of...
    Medical condition: Faecal incontinence
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10016092 Faecal incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) HU (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2010-023419-33 Sponsor Protocol Number: HZC112352 Start Date*: 2011-03-17
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: HZC112352:Estudio de 12 semanas de duración para evaluar la función pulmonar durante 24 horas de Furoato de Fluticasona /Vilanterol (FF/VI) 100/25 µg en polvo para inhalación, una vez al día, en co...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC) Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    13 10009725 EPOC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007107-32 Sponsor Protocol Number: M10-301 Start Date*: 2009-07-31
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-S...
    Medical condition: Non small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-000727-13 Sponsor Protocol Number: MRG106-11-201 Start Date*: 2018-12-17
    Sponsor Name:miRagen Therapeutics, Inc.
    Full Title: SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymp...
    Medical condition: Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028483 Mycosis fungoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021059-25 Sponsor Protocol Number: HZC113107 Start Date*: 2011-02-11
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Estudio de 12 semanas de duración para evaluar la función pulmonar durante 24 horas de Furoato de Fluticasona (FF)/Vilanterol (VI) en polvo para inhalación (FF/VI en polvo para inhalación) una vez ...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC) Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    13 10010952 EPOC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005393-32 Sponsor Protocol Number: M13-101 Start Date*: 2012-08-10
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV...
    Medical condition: Chronic Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) BE (Completed) HU (Completed) SE (Completed) AT (Completed) NL (Completed) IT (Completed) CZ (Prematurely Ended) IE (Completed) SK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002219-25 Sponsor Protocol Number: ITCA650-CLP-107 Start Date*: 2014-09-16
    Sponsor Name:Intarcia Therapeutics, Inc.
    Full Title: A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) EE (Completed) FI (Completed) DE (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:49:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA